Handelsavisen
prelaunch
Companies Healthcare 6576.TWO
65
6576.TWO TPEx Biotechnology & Medical Research

6576.Two

$79,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-199,9 %
ROE
-95,0 %
Net margin
-204,8 %
Debt / equity
0,25
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Business. 6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-95,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6576.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6576.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6576.TWO operates in the healthcare diagnostics industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    6576.TWO has a liquidity ratio of 3.44, indicating a strong ability to meet short-term obligations, but the company reported negative operating and free cash flows of -842,227,000 TWD and -830,516,000 TWD, respectively, suggesting potential liquidity challenges. The company's debt-to-equity ratio is 0.25, which is relatively low, indicating a conservative capital structure.

    In terms of profitability, 6576.TWO reported a net loss of -883,151,000 TWD and an operating loss of -862,316,000 TWD, with a return on equity of -0.95 and a return on assets of -0.674, both of which are significantly below the industry median for profitability metrics. These figures suggest that the company is currently not generating returns that meet industry standards.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may increase the company's exposure to market-specific risks.

    Looking at the growth trajectory, 6576.TWO has not provided specific numeric deltas for the current or next fiscal year, but the negative operating and free cash flows indicate a challenging growth environment. The company's recent financial performance suggests a need for strategic adjustments to improve profitability and cash flow.

    The risk assessment for 6576.TWO indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing. No significant dilution sources were identified in the recent filings or transcripts.

    Recent events, as disclosed in the company's filings, include a net loss and negative cash flows, which may impact investor confidence and the company's ability to fund its operations without additional financing.

    Key takeaways
    • 6576.TWO has a strong liquidity position with a current ratio of 3.44, but negative operating and free cash flows indicate potential liquidity challenges.
    • The company is not generating returns that meet industry standards, with a return on equity of -0.95 and a return on assets of -0.674.
    • Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
    • The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing.
    • No significant dilution sources were identified in the recent filings or transcripts.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $79,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $929.6M
    Net cash
    -$28.0M
    Current ratio
    3.4
    Debt / equity
    0.2
    ROA
    -67.4%
    ROE
    -95.0%
    Cash conversion
    95.0%
    CapEx / revenue
    -3.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-200,0 %Below median
    Net Margin-204,8 %Below median
    ROE-95,0 %Bottom quartile
    Capex / Rev-3,6 %Above median
    D/E0,25Bottom quartile
    Cash Conv0,95Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 6576.TWO Market data — financials · 2026-05-27
    • Foresee Pharmaceuticals Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6576.TWOCanonical
    TPEx · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage